title: [A comparative study on burn wound healing treated by different methods of recombinant human epidermal growth factor].
abstract: OBJECTIVE
  To explore an optimal method of recombinant human epidermal growth factor(rhEGF) application on the burn wounds of superficial II degree and profound II degree for accelerating its healing.
  
  
  METHODS
  There were 180 burn wounds in 60 patients with the self-corresponding wound of the same degree as controls. The wounds of all patients were divided three regions(A, B, C). The wounds were treated once a day with 1% SD-Ag in region A as controls, with rhEGF(40 U/cm2) in region B, and with a combination of rhEGF(40 U/cm2) and Su Yu Ping (5 g) in region C. The wound healing time was recorded and compared.
  
  
  RESULTS
  In regions A, B and C, the healing time of superficial II degree wound was (13.20 +/- 2.40) days, (10.20 +/- 2.20) days and (8.72 +/- 2.31) days (P < 0.01); that of profound II degree wound was (20.10 +/- 3.40) days, (17.20 +/- 3.12) days and (15.10 +/- 3.81) days respectively (P < 0.01, P < 0.05). The healed wound of profound II degree was elastic and tough in regions B and C, while that was not elastic and tough, and congestive in region A.
  
  
  CONCLUSIONS
  The above results indicate that rhEGF can enhance burn wound healing markedly and that a combination rhEGF and Su Yu Ping has more significant effect than rhEGF alone and is recommended for clinical application.
authors.affiliation: Department of Burn and Plastic Surgery, Affiliated Hospital, Luzhou Medical College, Luzhou, Sichuan, P. R. China, 646000.
authors.forename: Yi
authors.initials: Y
authors.lastname: Liao
authors.forename: Li
authors.initials: L
authors.lastname: Guo
authors.forename: Er-ying
authors.initials: EY
authors.lastname: Ding
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002056:Burns / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D004359:Drug Therapy, Combination; D004815:Epidermal Growth Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D004847:Epithelial Cells / Q000187:drug effects; D005260:Female; D006801:Humans; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D008081:Liposomes; D011994:Recombinant Proteins; D004815:Epidermal Growth Factor